{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["53"],"submitter":["Tuxen A"],"pubmed_abstract":["<h4>Background</h4>This study investigated excess risk in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) with or without elevated levels of NT-proBNP (N-terminal pro-brain natriuretic peptide).<h4>Methods</h4>Patients with HFrEF from the NorthStar cohort (n = 1120) were matched on age, sex, and presence of AF (atrial fibrillation/flutter) to five controls without HFrEF from The Danish National Patient Registries. Patients were compared with controls before and after stratification according to baseline NT-proBNP levels, with cutoffs defined as </≥ 600 pg/ml in patients with sinus rhythm and </≥ 900 pg/ml in patients with AF. The primary composite endpoint was a 7-year risk of cardiovascular death or HF admission.<h4>Results</h4>In the HFrEF cohort, 704 "],"journal":["International journal of cardiology. Heart & vasculature"],"pagination":["101441"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11368590"],"repository":["biostudies-literature"],"pubmed_title":["Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial)."],"pmcid":["PMC11368590"],"pubmed_authors":["Koeber L","Nouravesh N","Gustafsson F","Foesbol E","Schou M","Videbaek L","Malik M","Zahir D","Butt JH","Malmborg M","Jensen J","Andersson C","Tuxen A","Andersen CF"],"additional_accession":[]},"is_claimable":false,"name":"Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).","description":"<h4>Background</h4>This study investigated excess risk in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) with or without elevated levels of NT-proBNP (N-terminal pro-brain natriuretic peptide).<h4>Methods</h4>Patients with HFrEF from the NorthStar cohort (n = 1120) were matched on age, sex, and presence of AF (atrial fibrillation/flutter) to five controls without HFrEF from The Danish National Patient Registries. Patients were compared with controls before and after stratification according to baseline NT-proBNP levels, with cutoffs defined as </≥ 600 pg/ml in patients with sinus rhythm and </≥ 900 pg/ml in patients with AF. The primary composite endpoint was a 7-year risk of cardiovascular death or HF admission.<h4>Results</h4>In the HFrEF cohort, 704 ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-06-01T03:24:58.046Z","creation":"2024-11-15T21:28:48.358Z"},"accession":"S-EPMC11368590","cross_references":{"pubmed":["39228977"],"doi":["10.1016/j.ijcha.2024.101441"]}}